Saturday, October 15, 2016

Anbesol Liquid





1. Name Of The Medicinal Product



Anbesol Liquid


2. Qualitative And Quantitative Composition










Lidocaine hydrochloride Ph Eur




0.9%w/w




Chlorocresol Ph Eur




0.1%w/w




Cetylpyridinium chloride Ph Eur




0.02%w/w



3. Pharmaceutical Form



Liquid for oral administration



4. Clinical Particulars



4.1 Therapeutic Indications



For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething.



4.2 Posology And Method Of Administration



Adults, the elderly and children: Apply undiluted to the affected area with the fingertip. Two applications immediately will normally be sufficient to obtain pain relief. Use up to 8 times a day.



Babies teething: One application only. Do not repeat for at least half an hour. Use up to 8 times a day.



4.3 Contraindications



Patients with known history of hypersensitivity or allergic type reactions to any of the constituents of the product.



4.4 Special Warnings And Precautions For Use



If symptoms persist for more than 7 days consult your doctor or dentist. For babies teething, do not repeat for at least half an hour.



Keep all medicines out of the reach of children.



Do not exceed the stated dose.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None known.



4.6 Pregnancy And Lactation



No special precautions required.



4.7 Effects On Ability To Drive And Use Machines



None known.



4.8 Undesirable Effects



There have been reports of non-specific ulceration following oral cetylpyridinium chloride therapy.



4.9 Overdose



Ingestion of the complete contents of the marketed pack would not be expected to cause any adverse effects.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Lidocaine hydrochloride



Absorption and fate: lidocaine is readily absorbed from mucous membranes and through damaged skin. Lidocaine undergoes first-pass metabolism in the liver and about 90% is dealkylated to form monoethylglycinexylidide and glycinexylidide. Further metabolism occurs and the metabolites are excreted in the urine with less than 10% as unchanged lidocaine.



Chlorocresol



Absorption: there is no significant absorption of chlorocresol through the skin or mucous.



Cetylpyridinium chloride



Absorption: there is no significant absorption of cetylpyridinium chloride through the skin or mucous membranes.



5.2 Pharmacokinetic Properties



Lidocaine hydrochloride



White crystalline powder soluble in water and alcohol.



Mechanism of action/effect: lidocaine is a local anaesthetic of the amide type, which acts by reversible inhibition of nerve impulse generation and transmission.



Chlorocresol



Colourless crystals or a white crystalline powder slightly soluble in water and alcohol.



Chlorocresol has a disinfectant action.



Cetylpyridinium chloride



A white unctuous powder soluble in water and alcohol.



Mechanism of action/effect: cetylpyridinium chloride has a disinfectant action.



5.3 Preclinical Safety Data



None stated



6. Pharmaceutical Particulars



6.1 List Of Excipients



Alcohol 96%, menthol, glycerin, caramel colour*, purified water



*contains colorants E110, E104, E123, E142



6.2 Incompatibilities



None known



6.3 Shelf Life



36 months unopened



6.4 Special Precautions For Storage



Store at a temperature not exceeding 25°C



6.5 Nature And Contents Of Container



6.5ml, 15ml: glass bottles



6.6 Special Precautions For Disposal And Other Handling



Not applicable



7. Marketing Authorisation Holder



Alliance Pharmaceuticals Limited



Avonbridge House



Bath Road



Chippenham



Wiltshire



SN15 2BB



UK



8. Marketing Authorisation Number(S)



PL 16853/0128



9. Date Of First Authorisation/Renewal Of The Authorisation



30/07/1998



10. Date Of Revision Of The Text



21st July 2011





No comments:

Post a Comment